The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors
ConclusionLower DD rates are associated with several important healthy lifestyle behaviors. DD rate is a promising therapeutic target for new interventions to improve multiple health behaviors among CS. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Christine E. Sheffer,
Austin Miller,
Warren K. Bickel,
Julia A. Devonish,
Richard J. O ’Connor,
Chong Wang,
Cheryl Rivard,
Elizabeth A. Gage‐Bouchard Tags: Original Article Source Type: research
Cost ‐effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer
CONCLUSIONSThis modeling analysis found that both single and dual checkpoint blockade could be significantly more effective for MSI ‐H/dMMR mCRC than chemotherapy, but they were not cost‐effective, largely because of drug costs. Decreases in drug pricing and/or the duration of maintenance nivolumab could make ipilimumab and nivolumab cost‐effective. Prospective clinical trials should be performed to explore the optimal dur ation of maintenance nivolumab. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Jacqueline N. Chu,
Jin Choi,
Sassan Ostvar,
James A. Torchia,
Kerry Lynn Reynolds,
Angela Tramontano,
Justin F. Gainor,
Daniel C. Chung,
Jeffrey W. Clark,
Chin Hur Tags: Original Article Source Type: research
Real ‐world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis
ConclusionsThere have been rapidly changing practices in the testing and treatment patterns of patients with CLL within the last decade. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Erlene K. Seymour,
Julie J. Ruterbusch,
Jennifer L. Beebe ‐Dimmer,
Charles A. Schiffer Tags: Original Article Source Type: research
Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Tristan Tham Tags: Correspondence Source Type: research
Reply to Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: multicenter study from an endemic area in Southern China
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Jimmy Yu Wai Chan,
Wen Bo Huang,
Da Lie Liu Tags: Correspondence Source Type: research
A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited ‐stage small cell lung cancer in elderly patients versus younger patients
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Thomas E. Stinchcombe,
Wen Fan,
Steven E. Schild,
Everett E. Vokes,
Jeff Bogart,
Quynh ‐Thu Le,
Charles R. Thomas,
Martin J. Edelman,
Leora Horn,
Ritsuko Komaki,
Harvey J. Cohen,
Apar Kishor Ganti,
Herbert Pang,
Xiaofei Wang Source Type: research
Place of death for patients with cancer in the United States, 1999 through 2015: racial, age, and geographic disparities
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Fumiko Chino,
Arif H. Kamal,
Thomas W. Leblanc,
S. Yousuf Zafar,
Gita Suneja,
Junzo P. Chino Source Type: research
Adult leukemia survival trends in the United States by subtype: A population ‐based registry study of 370,994 patients diagnosed during 1995‐2009
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Chris Bailey,
Lisa C. Richardson,
Claudia Allemani,
Audrey Bonaventure,
Rhea Harewood,
Angela R. Moore,
Sherri L. Stewart,
Hannah K. Weir,
Michel P. Coleman,
CONCORD Working Group Source Type: research
The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Christine E. Sheffer,
Austin Miller,
Warren K. Bickel,
Julia A. Devonish,
Richard J. O ’Connor,
Chong Wang,
Cheryl Rivard,
Elizabeth A. Gage‐Bouchard Source Type: research
Cost ‐effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Jacqueline N. Chu,
Jin Choi,
Sassan Ostvar,
James A. Torchia,
Kerry Lynn Reynolds,
Angela Tramontano,
Justin F. Gainor,
Daniel C. Chung,
Jeffrey W. Clark,
Chin Hur Source Type: research
Real ‐world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Erlene K. Seymour,
Julie J. Ruterbusch,
Jennifer L. Beebe ‐Dimmer,
Charles A. Schiffer Source Type: research
Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Tristan Tham Source Type: research
Reply to Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: multicenter study from an endemic area in Southern China
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Jimmy Yu Wai Chan,
Wen Bo Huang,
Da Lie Liu Source Type: research
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of veterans health affairs data
CONCLUSIONSCetuximab with RT yields inferior OS in comparison with cisplatin for the nonoperative management of stage III to IVb HNSCC. According to this study, cisplatin may be the most appropriate partner for RT in this setting. (Source: Cancer)
Source: Cancer - October 20, 2018 Category: Cancer & Oncology Authors: Joshua M. Bauml,
Ravi Vinnakota,
Yeun ‐Hee Anna Park,
Susan E. Bates,
Tito Fojo,
Charu Aggarwal,
Jessica Di Stefano,
Christina Knepley,
Sewanti Limaye,
Ronac Mamtani,
Juan Wisnivesky,
Nevena Damjanov,
Corey J. Langer,
Roger B. Cohen,
Keith Tags: Original Article Source Type: research
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of veterans health affairs data
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 20, 2018 Category: Cancer & Oncology Authors: Joshua M. Bauml,
Ravi Vinnakota,
Yeun ‐Hee Anna Park,
Susan E. Bates,
Tito Fojo,
Charu Aggarwal,
Jessica Di Stefano,
Christina Knepley,
Sewanti Limaye,
Ronac Mamtani,
Juan Wisnivesky,
Nevena Damjanov,
Corey J. Langer,
Roger B. Cohen,
Keith Source Type: research
